TY  - JOUR

T1  - Cost-effectiveness analysis of contemporary first-line (1L) agents in locally advanced/metastatic urothelial carcinoma (la/mUC).

JO  - Journal of Clinical Oncology

UR  - https://doi.org/10.1200/jco.2024.42.16_suppl.4591

PY  - 2024/05/29

AU  - Naqvi SAA

AU  - Faisal KS

AU  - Raina A

AU  - Khakwani KZR

AU  - Riaz ZB

AU  - Shah VS

AU  - Cobran EK

AU  - Singh P

AU  - Hussain SA

AU  - Bryce AH

AU  - Riaz IB

ED  - 

DO  - DOI: 10.1200/jco.2024.42.16_suppl.4591

PB  - American Society of Clinical Oncology (ASCO)

VL  - 42

IS  - 16_suppl

SP  - 4591

EP  - 4591

Y2  - 2025/12/05

ER  -